Review

tyrosine kinase 1 (Bio-Techne corporation)

Bio-Techne corporation is a verified supplier

Bio-Techne corporation manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bio-Techne corporation tyrosine kinase 1
Tyrosine Kinase 1, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 73 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/neutralizing+antibodies+against+sflt-1/Camptothecin/pmc06028485-280-33-38
Average 93 stars, based on 73 article reviews

tyrosine kinase 1 - by Bioz Stars, 2026-09

93/100 stars

Images

Solvent:

Article Title: Exosome systems, products and methods
Article Snippet: .. Approximate Approximate lower wt % upper wt % Item wt % in amount amount # Ingredient Function Example acceptable acceptable 1 Water Solvent 78.35 60.00 90.00 2 Butylene Humectant 4.00 0.10 10.00 glycol 3 Lecithin Phospholipid 11.00 1.00 20.00 4 ε-poly-l- Preservative 0.05 0.00 0.50 lysine 5 K Sorbate Preservative 0.10 0.03 0.20 6 DMSO Solvent 0.50 0.01 2.00 7 Exosome Active 1.00 0.01 5.00 8 Hemp Oil Excipient(s) 5.00 1.00 10.00 Total 100.00 ..

Recombinant:

Article Title: SIRT1 ISGylation accelerates tumor progression by unleashing SIRT1 from the inactive state to promote its deacetylase activity
Article Snippet: .. Doxorubicin (D1515), camptothecin (S1288), cisplatin (S1166), and recombinant human IFN-alpha A (alpha 2a) (11100-1) were purchased from Sigma‒Aldrich, Selleckchem (Houston, TX, USA), Selleckchem, and R&D Systems (Minneapolis, MN, USA), respectively. .. HEK293T, HEK293FT, C-33A, HeLa, A549, MCF7, Huh7 and HepG2 cells were maintained at 37 °C in a 5% CO 2 atmosphere in DMEM (Welgene, Daegu, Korea) supplemented with 10% FBS (Gibco, Thermo Fisher, Waltham, MA, USA).

Image Search Results

Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and sFlt-1 in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.

Journal: Journal of Tissue Engineering

Article Title: Construction of a vascularized bladder with autologous adipose-derived stromal vascular fraction cells combined with bladder acellular matrix via tissue engineering

doi: 10.1177/2041731419891256

Figure Lengend Snippet: Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and sFlt-1 in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.

Article Snippet: Briefly, 2.5 × 10 5 SVFs were treated with five different concentrations of recombinant human Wnt5a (0, 10, 50, 100, and 200 ng/mL; R&D Systems, Minneapolis, MN, USA) or neutralizing antibodies against sFlt-1 (10 µg/mL; R&D Systems) premixed with Matrigel (1 mg/mL) and EGM-2, and injected subcutaneously into nude mice in both inguinal regions.

Techniques: Recombinant, Injection, Expressing

sFlt-1 suppresses the angiogenesis of SVFs: (a) Tube formation assays in SVFs treated with sFlt-1 neutralizing antibody, magnification ×40 and (b) Matrigel plug angiogenesis assay in SVFs treated with sFlt-1 neutralizing antibody. **p < 0.01.